To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Treatment Related to Urinary Tract Infections Is Associated with Delayed Diagnosis of Urinary Bladder Cancer: A Nationwide Population-based Study
Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden.
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
Department of Translational Medicine, Lund University, Malmö, Sweden.
Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.
Show others and affiliations
2025 (English)In: European Urology Oncology, E-ISSN 2588-9311, Vol. 8, no 1, p. 119-125Article in journal (Refereed) Published
Abstract [en]

BACKGROUND AND OBJECTIVE: It has been suggested that urinary tract infections (UTIs) are associated with delayed diagnosis of bladder cancer (BC). Our aim was to investigate prediagnostic treatments related to UTI and the relation to BC diagnostic delay, reflected by advanced disease at diagnosis. METHODS: We used data from the BladderBaSe 2.0 with data of treatments related to UTI up to 3 yr before BC diagnosis (2008-2019) for BC patients in comparison to a matched reference population. We investigated the association between UTI treatments and more advanced disease at diagnosis in the BC cohort. We used generalized ordered logistic regression to calculate odds ratios (ORs) for more advanced disease as an ordered outcome: non-muscle-invasive BC (NMIBC), muscle-invasive BC (MIBC), and metastatic BC (MBC). KEY

FINDINGS AND LIMITATIONS: The study population included 29 921 BC patients and 149 467 matched reference subjects. The proportions of individuals receiving UTI treatment were higher in the patient groups than in the corresponding reference groups, with the greatest differences observed for the MIBC and MBC subgroups. The OR for the risk of more advanced disease (MIBC or MBC) with at least one UTI treatment versus none was 1.28 (95% confidence interval [CI] 1.19-1.37) for men and 1.42 (95 % CI 1.27-1.58) for women. The association to risk of more advanced disease increased with the number of UTI treatments for both sexes.

CONCLUSIONS AND CLINICAL IMPLICATIONS: Further studies on the effects of treatments related to UTI in combination with other factors are needed to identify reasons for possible delays in the BC diagnostic pathway. PATIENT SUMMARY: We found that for patients with bladder cancer, previous antibiotic treatment for a urinary tract infection was linked to more advanced disease at diagnosis. Further studies are needed to identify reasons for possible delays in the diagnosis of bladder cancer.

Place, publisher, year, edition, pages
European Association of Urology, 2025. Vol. 8, no 1, p. 119-125
Keywords [en]
Bladder cancer, Diagnostic delay, Register-based study, Urinary tract infection
National Category
Clinical Medicine Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-115446DOI: 10.1016/j.euo.2024.07.008ISI: 001426105100001PubMedID: 39143001Scopus ID: 2-s2.0-85218503178OAI: oai:DiVA.org:oru-115446DiVA, id: diva2:1889817
Funder
Swedish Cancer Society, CAN 22 2021; CAN 2023/2807Swedish Research Council, 2021-00859Stiftelsen Gösta Jönssons forskningsfondStiftelsen Hillevi Fries forskningsfondLions Cancerforskningsfond i Norr, LP 23-2342
Note

This work was supported by the Swedish Cancer Society (grants CAN 22 2021 and CAN 2023/2807), the Swedish Research Council (2021-00859), Lund Medical Faculty, Skåne University Hospital Research Funds, The Cancer Research Fund at Malmö General Hospital, the Maud and Birger Gustavsson Research Foundation, the Hjelm Family Foundation for Medical Research, the Gösta Jönsson Research Foundation, the Foundation of Urological Research (Ove and Carin Carlsson bladder cancer donation), the Hillevi Fries Research Foundation, and the Lion’s Cancer Research Foundation in Northern Sweden (grant LP 23-2342).

Available from: 2024-08-16 Created: 2024-08-16 Last updated: 2025-03-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Jerlström, Tomas

Search in DiVA

By author/editor
Jerlström, Tomas
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
European Urology Oncology
Clinical MedicineCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 16 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf